ISRG

Intuitive SurgicalNASDAQ · Health Care Equipment · Health Care

Previous close

432.01

Change

−16.75 / −3.73%

FinDog View

Bullish

52-Week Range ?

328.57 – 603.88

P/E (TTM) ?

52.6

Forward P/E ?

34.3

Based on consensus earnings for the next 12 months

Market Cap

$151B

+6.24%

S&P 500 −0.91% over same period

Volume / Avg Volume

3.5M / 2.8M

1.26× average

Latest earnings analysisFY2026 Q3Reported 2026-10-20

Intuitive Q3 FY2026: revenue up 22.0%, non-GAAP EPS $3.00 despite $450 million charge

Intuitive beat on the numbers that repeat: revenue rose 22.0% to $3.05 billion, procedures grew 15%, and non-GAAP EPS of $3.00 topped the $2.6954 consensus. GAAP EPS of $1.49 looks ugly only because a $450 million antitrust settlement landed in the quarter. Read the non-GAAP line for the underlying business, and the cash flow line for what it funds.

Read the full analysis →

Revenue$3.05BYoY +21.70%

EPS (non-GAAP)$3.00Beatest. $2.70

Next-day move−2.26%

Price History

Closing price · USD1M 6M 1Y 5Y

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 75.61M 6M 1Y 5Y

Recent Earnings

Click to read the FinDog analysis

Period	Reported	Revenue	EPS Actual / Est.	Next-Day Move	Analysis
FY2026 Q3 Quarter ended 2026-09	2026-10-20	$3.0B	3.00 / 2.70	−2.26%	Read analysis →
FY2026 Q2 Quarter ended 2026-06	2026-07-16	$2.9B	2.80 / 2.55	−14.15%	Read analysis →
FY2026 Q1 Quarter ended 2026-03	2026-04-21	$2.8B	2.50 / 2.14	+7.16%	Pending
FY2025 Q4 Quarter ended 2025-12	2026-01-14	$10.1B	2.53 / 2.30	−0.99%	Pending
FY2025 Q3 Quarter ended 2025-09	2025-10-21	$2.5B	2.40 / 2.02	+13.89%	Pending
FY2025 Q2 Quarter ended 2025-06	2025-07-22	$2.4B	2.19 / —	−1.77%	Pending
FY2025 Q1 Quarter ended 2025-03	2025-04-23	$2.3B	1.92 / —	+4.14%	Pending

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →

Report date

2027-01-20

in 80 days · After hours

Consensus EPS

$2.90

Last quarter EPS $3.00

Avg. next-day move over the last 7 reports

±6.3%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data

Valuation

P/E is at percentile 15 of its 5-year rangeCheap

5-year range 45.4 – 90.5 · Median 75.6

Last 4 quarters: $4.6B in buybacks + $0 in dividends, 3.05% of market cap combined

P/E (TTM)

52.6

P/B

9.7

P/S

13.4

PEG

2.05

Earnings Reaction

Over the last 7 reports, the stock moved ±6.3% on average on the first trading day after, rising 3 times

Most recent −2.26%

Volatility & Correlation

1-year beta 0.89 · Correlation with S&P 500 0.33Tracks the market

Annualized volatility 34% vs. 13% for the S&P 500

Insider Trading

View all →

Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions

Buy 0 · $0.00MSell 21 · $16.9MNet selling $16.9M

10-28Brosius MarkEVP & Chief Mfg and Supply ChaSell$0.03M61 shares · Avg price 441.60
10-27Brosius MarkEVP & Chief Mfg and Supply ChaSell$0.03M61 shares · Avg price 451.63
10-26Brosius MarkEVP & Chief Mfg and Supply ChaSell$0.03M61 shares · Avg price 451.75
10-23GUTHART GARY SDirectorSell$9.1M20,095 shares · Avg price 451.61
10-23WADORS PATRICIA LSVP Chief Human Resources OffiSell$0.48M1,078 shares · Avg price 443.80
10-23Widman FredrikVP Corporate ControllerSell$1.8M4,047 shares · Avg price 453.21
10-23BARRATT CRAIG HDirectorSell$0.51M1,150 shares · Avg price 443.80
09-15Widman FredrikVP Corporate ControllerSell$0.41M1,089 shares · 2 trades · Avg price 374.44

Multi-Quarter Financial Trends

View all quarters →

Last 12 quarters · As reported by the company

Quarter	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Free Cash Flow ($B)	EPS
FY2026 Q3	3.05	+21.7%	68.4%	0.59	0.52	1.22	1.49
FY2026 Q2	2.89	+18.5%	67.8%	0.97	0.82	1.06	2.29
FY2026 Q1	2.77	+23.0%	66.1%	0.86	0.82	0.91	2.28
FY2025 Q4	2.87	+18.8%	66.4%	0.86	0.79	0.89	2.19
FY2025 Q3	2.51	+22.9%	66.4%	0.76	0.70	0.84	1.95
FY2025 Q2	2.44	+21.4%	66.3%	0.74	0.66	0.72	1.81
FY2025 Q1	2.25	+19.2%	64.7%	0.58	0.70	0.58	1.92
FY2024 Q4	2.41	+25.2%	68.0%	0.73	0.69	0.82	1.89
FY2024 Q3	2.04	+16.9%	67.4%	0.58	0.57	0.71	1.56
FY2024 Q2	2.01	+14.5%	68.3%	0.57	0.53	0.62	1.46
FY2024 Q1	1.89	+11.5%	65.9%	0.47	0.54	0.27	1.51
FY2023 Q4	1.93	+16.5%	66.2%	0.45	0.61	0.23	1.69

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →

Ticker	Company	Market Cap	P/E	Revenue YoY	Gross Margin	1M	View
ISRG	Intuitive Surgical	$151B	52.6	+21.7%	68.4%	+6.24%	Bullish
LLY	Lilly (Eli)	$1.34T	50.2	+38.6%	83.9%	+22.51%	Bullish	Compare
JNJ	Johnson & Johnson	$666B	41.3	+5.9%	68.1%	+3.20%	Bullish	Compare
ABBV	AbbVie	$522B	81.4	+10.2%	74.7%	+12.73%	Bullish	Compare
UNH	UnitedHealth Group	$367B	23.0	+0.4%	88.1%	+10.87%	Bullish	Compare
MRK	Merck & Co.	$371B	117.2	+5.1%	73.5%	+2.90%	Neutral	Compare
TMO	Thermo Fisher Scientific	$258B	36.4	+9.1%	—	+3.25%	Neutral	Compare
AMGN	Amgen	$254B	28.5	+9.5%	72.0%	+10.56%	Bullish	Compare
GILD	Gilead Sciences	$213B	—	+6.8%	81.1%	+14.51%	Neutral	Compare

The View in One Line

Revenue up 21.7% and non-GAAP EPS $3.00 beat by 11.3%; the profit dip is a $450M settlement. Bullish if procedure growth holds 14-15%.

Updated 2026-10-30

Notable Institutional Holders

Coatue Management$316MReduced −7%
Renaissance Technologies$201MAdded +262%
Citadel Advisors · Ken Griffin$187MReduced −65%
ARK Invest · Cathie Wood$28.0MAdded +2%
Bridgewater Associates · Ray Dalio$7.7MAdded +12%

As of 2026-06-30

ETFs holding it

XLV Health Care Select Sector SPDR Fund2.27%
QQQ Invesco QQQ0.71%
JEPQ JPMorgan Nasdaq Equity Premium Income ETF0.71%
QQQM Invesco NASDAQ 100 ETF0.70%
SCHG Schwab U.S. Large-Cap Growth ETF0.61%
JEPI JPMorgan Equity Premium Income ETF0.58%
VUG Vanguard Growth ETF0.44%
VOO Vanguard S&P 500 ETF0.23%

Weights estimated at latest prices

Key Events

07-27Governance
Intuitive Surgical Amends Articles of Incorporation and Bylaws
On July 23, 2026, Intuitive Surgical's board amended and restated its articles of incorporation, covering changes to shareholder nomination disclosures, proxy rules and voting standards.Source ↗
05-28Management Change
Intuitive Surgical Chief Commercial Officer Moves to New Role July 1
Henry L. Charlton will step down as Chief Commercial and Marketing Officer on July 1, 2026 and become Senior Vice President of Global Business Operations, with Taylor Patton succeeding him in the role.Source ↗
05-04Governance
Annual Meeting Passes Director Elections and Share Buyback Plan
On April 30, 2026, Intuitive Surgical held its annual meeting, electing ten directors, approving executive compensation, reappointing PwC, and authorizing up to $5 billion in share repurchases.Source ↗

Key Financial Trends

Quarterly Revenue ($B)3.0

Gross Margin68.4%

Free Cash Flow ($B)1.2